December 18, 2024
- New Zantac Cancer Lawsuits Filed: Despite the recent settlement with GlaxoSmithKline, new Zantac lawsuits continue to be filed against other manufacturers. A recent lawsuit filed in Delaware alleges that long-term Zantac use caused the plaintiff's bladder cancer.
December 15, 2024
- Philadelphia Zantac Trials Postponed: Four bellwether trials scheduled in Philadelphia between March and November 2025 have been postponed due to an appeal regarding the recusal of the presiding judge. New trial dates will be determined after the appeal is resolved.
December 3, 2024
- New Breast Cancer Lawsuit Filed Against GSK: A California woman has filed a lawsuit against GlaxoSmithKline, alleging that her long-term use of Zantac caused her breast cancer. The lawsuit claims that the ranitidine in Zantac exposed her to NDMA, a probable carcinogen.
November 22, 2024
- Mistrial Declared in California Zantac Case: A mistrial was declared in a California Zantac case after the jury failed to reach a unanimous verdict on whether the drug contributed to the plaintiff's bladder cancer. The jury did agree that Zantac was dangerous and that the company failed to warn about its risks.
October 9th, 2024
- Zantac Class Action Settlement Announced: GSK has agreed to pay up to $2.2 billion to settle most (93%) pending U.S. state court lawsuits claiming that a discontinued version of the heartburn drug Zantac caused cancer. The settlement with ten plaintiffs' law firms resolves about 80,000 cases nationwide.
October 8, 2024
- New Zantac Trial Focuses on Bladder Cancer: A new Zantac trial has commenced in Oakland, California, this time focusing on a plaintiff with bladder cancer, a cancer type with a stronger link to NDMA (a probable carcinogen found in ranitidine). The defense's opening statement attributed the plaintiff's cancer to secondhand smoke and weight, rather than Zantac, a claim that may be difficult to prove. This trial is crucial for plaintiffs seeking a win after a string of unfavorable outcomes in previous Zantac trials.
October 7, 2024
- Zantac Appeal in Delaware Highlights Expert Testimony Dispute: Defendants have filed their appeal brief in the Delaware Supreme Court, challenging the lower court's decision to allow certain expert testimony. The defendants argue that the plaintiffs' experts failed to establish a specific "threshold dose" for ranitidine or NDMA to be considered a cancer risk. Plaintiffs counter that this requirement is overly rigid and inconsistent with Delaware's more nuanced approach to evaluating scientific evidence. The outcome of this appeal could have significant implications for the admissibility of expert testimony in future Zantac trials.
September 27, 2024:
- First California Zantac Trial Set to Begin: After settling all previous Zantac cases heading for trial in California, the defendants are now seemingly prepared to test their luck. The first Zantac trial in the state is scheduled to commence with jury selection next week in Alameda County Superior Court in Oakland. The trial itself is expected to start on October 7, 2024. Its outcome will be closely monitored, as it could significantly influence the trajectory of future Zantac lawsuits nationwide.
September 24, 2024:
- Zantac Trials Hit a Snag: Another Illinois Zantac lawsuit ended in a mistrial last week, leaving plaintiffs with a record of 0 wins, 2 losses, and 2 hung juries. This pattern, while frustrating for those seeking compensation, aligns with the defense's tactic of settling strong cases and gambling on weaker ones at trial. The focus on cancer types like colorectal and prostate, which have less established links to Zantac, further complicates plaintiffs' path to victory. It's a tough fight, but remember, a lack of verdicts against the drug companies doesn't erase the potential dangers of Zantac.
September 18, 2024:
- GSK Settles Two Zantac Cases in California: GSK announced today that it has reached confidential settlements in two Zantac cases filed in California State Court. The cases involved John Russell, who claimed bladder cancer, and Annette Hughes, who claimed colorectal cancer. GSK maintains that it does not admit any liability in these settlements and the cases will be dismissed against the company.
August 27, 2024:
- Delaware Supreme Court to Hear Zantac Appeal: A Delaware court has agreed to hear an appeal by GSK, Pfizer, Sanofi, and Boehringer Ingelheim seeking to dismiss thousands of lawsuits alleging that the discontinued heartburn drug Zantac caused cancer. The drugmakers argue that the plaintiffs' expert testimony on the alleged cancer link lacks scientific validity. This appeal's outcome could significantly impact the future of Zantac litigation, potentially allowing the lawsuits to proceed to trial or hindering the plaintiffs' ability to prove their claims.
August 26, 2024:
- Zantac Lawsuits to Proceed in Connecticut State Court: A Connecticut state court judge denies motions to dismiss filed by major Zantac manufacturers, allowing consolidated lawsuits alleging a link between Zantac and cancer to continue. The defendants had challenged the court's jurisdiction, particularly over "innovator liability" claims, but the court upheld its jurisdiction based on the companies' significant business activities in Connecticut and their consent to jurisdiction by registering to do business in the state.
August 19, 2024:
- Florida Judge Rejects Plaintiffs' Experts in Zantac Lawsuit: A Florida judge rules against the plaintiffs in a Zantac lawsuit by rejecting their expert witnesses. This decision reinforces the challenges faced by plaintiffs in pursuing Zantac litigation in Florida state court, further highlighting the state's less favorable environment for such cases.
August 19, 2024:
- Judge Denies Recusal Request in Philadelphia Zantac Litigation: Judge Joshua Roberts, overseeing Philadelphia's Zantac mass tort litigation, denies a motion for his recusal filed by plaintiffs. The plaintiffs had expressed concerns about a potential conflict of interest due to his wife's employment at Reed Smith, a law firm representing GlaxoSmithKline in other Zantac litigation. Judge Roberts stated that he does not believe his impartiality would be compromised, acknowledging the sensitivity of the situation but finding the connection between his wife's work and the firm's blog posts on the litigation insufficient grounds for recusal.
August 8, 2024:
- Mistrial in Illinois Zantac Prostate Cancer Trial: An Illinois state judge declared a mistrial in a lawsuit alleging that Boehringer Ingelheim's Zantac caused the plaintiff's prostate cancer. The jury was unable to reach a unanimous verdict. This follows another recent defense verdict in an Illinois Zantac case involving colorectal cancer.
August 5, 2024:
- GSK Wins Zantac Trial in Illinois: A jury in an Illinois state court found that GlaxoSmithKline's Zantac was not responsible for a plaintiff's colorectal cancer, marking the second consecutive loss for plaintiffs in Zantac litigation.
July 28, 2024:
- GSK Settles Another Zantac Lawsuit: GlaxoSmithKline reportedly settled another Zantac lawsuit involving prostate cancer, but continues to resist wider payouts to resolve the numerous similar claims in the U.S. court system.
July 25, 2024:
- Federal Appeals Court Returns Zantac Cancer Lawsuits to Connecticut State Court: The U.S. Court of Appeals for the Second Circuit rules that nine Zantac lawsuits, involving over 850 plaintiffs who allege they developed cancer after using the recalled heartburn drug, should be remanded back to Connecticut state court. The judges noted that the lawsuits were structured to avoid federal jurisdiction, where similar claims have been dismissed.
July 20, 2024:
- Two Zantac Trials Underway: Two Zantac trials are currently in progress. One is a colorectal cancer lawsuit (Joiner v. GlaxoSmithKline), and the other involves a claim that NDMA in Zantac caused the plaintiff's prostate cancer (Gross v. Boehringer Ingelheim). GlaxoSmithKline had previously settled with the plaintiff in the latter case.
July 19, 2024:
- New Zantac Trial Focuses on Colorectal Cancer: A new Zantac trial commences in state court against GlaxoSmithKline and Boehringer Ingelheim. Unlike the MDL, which focused on five specific types of cancer (bladder, liver, pancreatic, stomach, and esophageal), this trial centers on a colorectal cancer lawsuit, demonstrating the expanded scope of Zantac litigation in state courts.
July 11, 2024:
- Plaintiffs Seek Recusal of Judge in Philadelphia Mass Tort: Plaintiffs in Philadelphia's Zantac mass tort litigation request the recusal of Judge Joshua Roberts due to a potential conflict of interest. They argue that Judge Roberts' wife's employment at Reed Smith, a law firm representing GlaxoSmithKline in national litigation, could create an appearance of impropriety and potential bias.
July 8, 2024:
- New Zantac Lawsuits Filed in Delaware: A group of plaintiffs suffering from various cancers, including colorectal/colon cancer, prostate cancer, and breast cancer, filed a lawsuit against Zantac manufacturers GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Sanofi, and Patheon in Delaware state court.
July 3, 2024:
- Drugmakers' Appeal to End Zantac Cancer Lawsuits Rejected: A Delaware judge denied a request by GSK and other drugmakers to appeal a ruling allowing over 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to proceed. The drugmakers, including Pfizer, Sanofi, and Boehringer Ingelheim, will now need to seek permission to appeal directly from the Delaware Supreme Court. GSK has already submitted its appeal. If denied there, Zantac cases may be cleared for trial.
July 2, 2024:
- GSK Settles Another Zantac Lawsuit: GSK reaches a confidential settlement in an Illinois Zantac lawsuit, where the plaintiff alleged their prostate cancer was caused by Zantac use. This marks another case resolved as GSK continues to address the extensive personal injury litigation related to the heartburn medication.
July 1, 2024:
- Zantac MDL Cases Decrease: The Zantac MDL has seen a reduction in active cases, dropping from 14,401 in June to 2,422 in July 2024. However, the focus of Zantac litigation is shifting towards state courts, particularly in Delaware and California.
June 20, 2024:
- Industry Groups Support Zantac Appeal: Leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America, filed a friend-of-the-court brief in support of GSK and other drugmakers' appeal to halt over 70,000 Zantac cancer lawsuits in Delaware. The groups argue that the judge’s recent ruling allowing 70,000 lawsuits to proceed threatens Delaware's business-friendly reputation and could turn the state into a hub for mass tort litigation.
June 3, 2024
- A Delaware judge allowed more than 70,000 Zantac Class Action lawsuits to proceed after alleging its discontinued heartburn drug Zantac from GSK caused multiple types of cancers. GSK said it would immediately appeal. The ruling means that the cases will face jury trial with scientific experts.
May 8, 2024
- Pfizer has agreed to settle more than 10,000 Zantac Class Action lawsuits which alleged that the company failed to warn patients about possible cancer risks caused by the anti-heartburn medication Zantac.
2024 Overview
- Over the past 12 months, GSK has settled a series of lawsuits related to Zantac, including several in California.
Click Here for a FREE Claim Review from a Zantac Class Action Lawyer
Zantac, once a household name for those dealing with heartburn and ulcers, has been entangled in a serious health concern that led to its recall. What began as a groundbreaking medication has turned into a source of anxiety for many. Let’s explore concerns about Zantac and the impact on public health.
The rise and fall of Zantac
Introduced by Glaxo (now GlaxoSmithKline) in 1981, Zantac required a doctor’s prescription and quickly gained trust as an effective medication. By the late 1980s, its popularity soared, becoming the world's most prescribed drug. As it transitioned to over-the-counter status, its usage became even more widespread for heartburn and stomach ulcers.
However, after four decades of common use, unsettling research began to surface. Studies indicated a link between Zantac's active ingredient, ranitidine, and various types of cancers due to the formation of NDMA, a cancer-causing chemical.
Fill out the form on this page for more information.
The turning point: Recognizing the risks
It was in 2019 when the FDA announced that tests revealed the presence of NDMA in ranitidine products. The response was swift—manufacturers initiated voluntary recalls, and by early 2020, the FDA called for a complete withdrawal of all Zantac products from the market.
The Zantac cancer connection: A troubling discovery
The link between Zantac and cancer is particularly distressing. NDMA, found in degraded ranitidine–a known carcinogen– has been associated with several types of cancer. Notable among these are:
- Breast cancer: Research suggests a significant risk increase, particularly ductal carcinoma and estrogen receptor-positive/progesterone receptor-positive ductal carcinoma.
- Bladder cancer: Studies have indicated a substantial risk, especially with prolonged usage.
- Uterine cancer: Animal studies have suggested a connection to uterine cancer, with human observational studies supporting these findings.
- Prostate cancer: Exposure to NDMA has been linked to a higher incidence of prostate cancer and mortality.
- Liver cancer: The evidence points to an increased risk following the use of ranitidine.
- Gastric cancer: The risk appears to extend throughout the gastric system, with some studies showing alarming increases in risk percentages.
- Colorectal cancer: A significant jump in risk percentage has been associated with the use of Zantac.
- Infant testicular cancer: There is a concern over exposure in utero leading to testicular cancer in infants.
Beyond cancer, exposure to NDMA through ranitidine could contribute to several non-cancerous illnesses. Notably, these include Crohn’s disease, liver disease, and pulmonary hypertension—conditions that also have profound impacts on health and quality of life.
Click Here for a FREE Claim Review from a Zantac Class Action Lawyer
The shadow of silence: Did Glaxo know?
Central to the ongoing litigation is the question of whether GlaxoSmithKline was aware of the risks and chose not to inform the public. This concern raises profound ethical questions about the responsibilities of pharmaceutical companies and the transparency required in the healthcare industry.
Legal and regulatory challenges
The fallout from the discovery of NDMA in Zantac has led to a flurry of legal actions. Thousands of individuals who used Zantac and later developed cancer have filed lawsuits against the manufacturers. These Zantac lawsuits claim that the companies failed to warn consumers about the potential risk of cancer from ranitidine use.
On the regulatory front, the FDA's decision to withdraw Zantac from the market underscores the agency's commitment to public safety. However, it also highlights the challenges in monitoring long-established medications and ensuring they remain safe for consumption over time.
The impact on public health and trust
The recall of Zantac and the subsequent lawsuits have had a significant impact on public health and trust in pharmaceuticals. For many, the incident has raised concerns about the long-term safety of commonly used medications and the thoroughness of pre-market testing.
Furthermore, the situation has led to increased scrutiny of other medications and their ingredients, with regulators and consumers alike demanding more transparency and accountability from pharmaceutical companies.
What consumers can do
For individuals who have used Zantac or ranitidine products, staying informed about the ongoing research and legal proceedings is crucial. Those concerned about their health should consult their healthcare provider to discuss alternative treatments for heartburn and related conditions.
If you or someone you care about has taken Zantac and subsequently developed cancer or tragically passed away, you might be eligible for compensation. This situation has not only brought to light significant health risks associated with a widely used medication but also the potential for legal recourse for those affected. It's important to explore your options and understand your rights in this matter.
Seeking advice from a legal professional who is knowledgeable about the ongoing litigation against Zantac manufacturers could provide you with the necessary guidance to pursue a claim.
Click Here for a FREE Claim Review from a Zantac Class Action Lawyer
____________________________________________________________________________________________________________
Mass torts vs. class actions at a glance
When we're talking about mass tort and class action lawsuits, we're discussing two distinct legal approaches used to handle claims where many individuals are harmed by the same entity or event.
Mass tort lawsuits are a way to handle legal cases where many individuals have been harmed, but each person's situation is distinct. Think of it like a neighborhood where every house has different damage after a storm. In a mass tort, each homeowner would file their own lawsuit, but because the storm is the common factor, the court groups the lawsuits together to manage them more efficiently. The key here is that each person retains their own case and has a say in how it's settled, which reflects their unique damages.
In contrast, class action lawsuits and class action settlements bring people together under a single legal action. It's as if the whole neighborhood decided to sue the storm together, with one or a few neighbors representing everyone's interests. Here, individual control is limited. The representative, known as the lead plaintiff, along with their legal team, makes decisions that affect the entire group. When it comes to the payout, it's typically split evenly, or based on a formula that applies to all members.
What's best for you?
Let's quickly sum up the main points to help you decide which legal route could work better for your situation:
- Control: More personal control in mass torts; limited control in class actions.
- Compensation: Individualized in mass torts; uniform in class actions.
- Applicability: Mass torts fit for varied individual damages; class actions for uniform damages across the group.
- Efficiency: Class actions can be quicker and use fewer resources by combining claims.
So, if you're part of a group that's been wronged and you're thinking about legal action, consider these points. Do you need to maintain control over your case, or are you okay with a representative taking the lead? Do your damages require individual attention, or are they similar enough to others to share in a collective claim? Your answers will help determine whether a mass tort or a class action is the best route for your situation.
Click Here for a FREE Claim Review from a Zantac Class Action Lawyer
